Cases & Deals

TAP Pharmaceutical successfully defends 19 Lupron® pricing actions in state and federal courts

Clients TAP Pharmaceutical Products Inc.

Jones Day successfully defended TAP Pharmaceutical Products, Inc., the manufacturer of a leading prostate cancer drug, Lupron®, in 19 putative class actions in federal and state courts, alleging RICO and other fraud-based claims on the contention that TAP artificially inflated the average wholesale price for Lupron®. Jones Day attorneys took lead roles in obtaining dismissal of several counts in the MDL action, including the count for common law fraud; reversing certification of a national class in the North Carolina litigation; successfully opposing a certification of a national class in the New Jersey litigation; and securing preliminary and final approval of the class action settlement in MDL 1430 -- including a successful opposition of a Rule 23(f) petition and appeal of the preliminary settlement approval order. The settlement was ultimately approved on mutually agreeable terms.

In re Lupron® Marketing and Sales Practices Litigation, MDL No. 1430, Various State Docket Numbers

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.